Trials / Completed
CompletedNCT04016636
A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia
"Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia (CLL): Argentinian Experience"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Mela Osorio Maria Jose · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The aim of this study is to evaluate the impact of Ibrutinib monotherapy in the QoL of subjects with Chronic Lymphocytic Leukemia (CLL) based in European Quality of Life 5 Dimensions (EQ-5D) and FACIT- fatigue questionnaires assessment from baseline to 1 year of treatment in Argentinian routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Standard of Care | Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months. |
Timeline
- Start date
- 2019-08-12
- Primary completion
- 2021-08-30
- Completion
- 2022-10-15
- First posted
- 2019-07-11
- Last updated
- 2023-02-16
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT04016636. Inclusion in this directory is not an endorsement.